Lakefront Biotherapeutics (GLPGF) Gains from Sales and Divestitures (2018 - 2019)
Lakefront Biotherapeutics' (GLPGF) quarterly Gains from Sales and Divestitures came in at $1106.9 in Q4 2019, up 100.14% year-over-year from $553.04 in Q4 2018, and up 100.14% quarter-over-quarter from -$765877.0 in Q4 2018.
Powered by 
Analysis
Lakefront Biotherapeutics (GLPGF) Gains from Sales and Divestitures (2018 - 2019) Analysis & Trends
Lakefront Biotherapeutics (GLPGF) has reported Gains from Sales and Divestitures for 2 consecutive years, with $1106.9 the latest figure, recorded in Q4 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.28 Bn | 197.29 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 181.28 Bn | 178.10 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.26 Bn | 124.41 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.58 Bn | 74.58 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.67 Bn | 56.48 Bn | 1.37 Bn |
| 6 | Moderna | 54.58 Bn | 49.44 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.01 Bn | 30.70 Bn | 992.69 Mn |
| 8 | Biogen | 31.26 Bn | 29.98 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.78 Bn | 29.78 Bn | 1.16 Mn |
| 10 | Lakefront Biotherapeutics | 1.73 Bn | 1.73 Bn | 3.51 Mn |